WO2015102019A2 - Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride - Google Patents

Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride Download PDF

Info

Publication number
WO2015102019A2
WO2015102019A2 PCT/IN2014/000801 IN2014000801W WO2015102019A2 WO 2015102019 A2 WO2015102019 A2 WO 2015102019A2 IN 2014000801 W IN2014000801 W IN 2014000801W WO 2015102019 A2 WO2015102019 A2 WO 2015102019A2
Authority
WO
WIPO (PCT)
Prior art keywords
cyano
butyl
piperazinyl
indol
reaction mixture
Prior art date
Application number
PCT/IN2014/000801
Other languages
French (fr)
Other versions
WO2015102019A3 (en
Inventor
Srinivasan Thirumalai Rajan
Sajja Eswaraiah
Gogulapati Venkata Panakala Rao
Original Assignee
Msn Laboratories Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Private Limited filed Critical Msn Laboratories Private Limited
Priority claimed from IN732CH2014 external-priority patent/IN2014CH00732A/en
Priority claimed from IN6150CH2013 external-priority patent/IN2013CH06150A/en
Publication of WO2015102019A2 publication Critical patent/WO2015102019A2/en
Publication of WO2015102019A3 publication Critical patent/WO2015102019A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention provides a formic acid salt as well as its crystalline form of antidepressant drug i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la, which is useful in the preparation of 5-[4-[4-(5- cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb and process for its preparation.
  • antidepressant drug i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la, which is useful in the preparation of 5-[4-[4-(5- cyano- 1 H-indol-3-yl)
  • US7834020 (hereafter referred to as "020") describes several crystalline forms of vilazodone hydrochloride, such as Form-I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XIII, XIV, XV and XVI and process for their preparation.
  • Discovering new polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, e.g., better processing or handling characteristics, improved dissolution profile or improved shelf-life.
  • the present invention involves the novel crystalline forms of as acid addition salts of vilazodone.
  • the present invention also provides novel acid addition salts of vilazodone in solid state form.
  • novel salts of vilazodone of the present invention can be used to prepare vilazodone free base in pure form, which in turn useful in the preparation of highly pure vilazodone hydrochloride.
  • the first aspect of the present invention is to provide formic acid salt of 5-[4-[4-(5- cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la and its crystalline form herein after designated as Form-M.
  • the second aspect of the present invention is to provide a process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la.
  • the third aspect of the present invention is to provide a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
  • the fourth aspect of the present invention is to provide an alternate process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofurancarboxamide hydrochloride compound of formula- lb.
  • the fifth aspect of the present invention is to provide a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
  • the sixth aspect of the present invention is to provide a micro crystalline cellulose (MCC) pre-mixed 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient.
  • MCC micro crystalline cellulose
  • the seventh aspect of the present invention is to provide a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient.
  • the eighth aspect of the present invention is to provide a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient.
  • Figure 1 Illustrates the PXRD pattern of crystalline Form-M of formic acid salt of 5-[4-[4-
  • Figure 2 Illustrates the DSC thermogram of crystalline Form-M of formic acid salt of 5-[4- [4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide.
  • Figure 3 Illustrates the IR spectrum of crystalline Form-M of formic acid salt of 5-[4-[4-(5- cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide.
  • Figure 4 Illustrates the PXRD pattern of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-3.
  • Figure 5 Illustrates the DSC thermogram of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-3.
  • Figure 6 Illustrates the PXRD pattern of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-4.
  • Figure 7 Illustrates the PXRD pattern of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-5 or example -6.
  • Figure 8 Illustrates the PXRD pattern of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-7.
  • Figure 9 Illustrates the PXRD pattern of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yl)butyl) piperazin-l-yl)benzofuran-2-carboxylate hydrochloride
  • suitable solvent is selected from “alcoholic solvents” such as methanol, ethanol, isopropanol, n-propanol, n-butanol, iso-butanol, ethylene glycol and the like; “ester solvents” such as ethyl acetate, methyl acetate, n-butyl acetate, isobutyl acetate, sec-butyl acetate, isopropyl acetate and the like, “ether solvents” such as tetrahydrofuran, diethylether, methyl tert-butylether, 1 ,4-dioxane and the like; “hydrocarbon solvents” such as toluene, xylene, cyclohexane, hexane, heptane, n-pentane and the like; “chloro solvents” such as methylene chloride, ethylene dichloride, carbon tet
  • suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like.
  • MCC micro crystalline cellulose
  • the first aspect of the present invention provides a formic acid salt of 5-[4-[4-(5- cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide and its crystalline form herein after designated as Form-M.
  • the said crystalline form-M is characterized by: a) Its powder X-ray diffractogram having peaks at 7.2, 7.7, 8.5, 10.4, 11.9, 12.2, 14.4, 14.7, 15.5, 16.6, 17.2, 18.0, 19.1, 20.0, 20.5, 21.0, 21.4, 21.9, 23.2, 24.0, 24.6, 26.4, 27.0 and 29.3 and 29.9 degrees of two-theta as illustrated in figure- 1 ;
  • the second aspect of the present invention provides a process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la, comprising of the following steps:
  • the suitable solvent is selected from ester solvents, ketone solvents, chloro solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof;.
  • the preferred embodiment of the present invention provides a process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide, comprising of the following steps:
  • the preferred embodiment of the present invention provides a process for the preparation of crystalline Form-M of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide, comprising of the following steps:
  • the starting material i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide utilized in the present invention can be prepared by any of the known prior art process.
  • the third aspect of the present invention provides a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]- l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps: a) Dissolving the formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl] -2-benzofuran carboxamide in a suitable acid,
  • the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like;
  • the suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry HC1, ethyl acetate-HCl, IPA-HC1, ethanol-HCl, methanol-HCl;
  • step-d) the suitable solvent is same as defined in step-b) of the second aspect of the present invention.
  • the preferred embodiment of the present invention provides a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]- 2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
  • the preferred embodiment of the present invention provides a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]- 2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
  • the fourth aspect of the present invention provides an alternate process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
  • the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like;
  • the suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry
  • the suitable solvent is selected from ester solvents, ketone solvents, chloro
  • solvents alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof; preferably the suitable solvent is selected from polar solvents such as water.
  • the preferred embodiment of the present invention provides an alternate process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps:
  • 5 - [4- [4-(5 -cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride form-XVI obtained according to the above aspect of the present invention is characterized by its X-ray powder diffractogram having peaks at 7.8, 8.6, 10.5, 12.3, 14.8, 16.6, 19.4, 20.1, 21.1, 22.4, 23.6, 24.3, 24.5, 26.7, 27.2 and 31.6 ⁇ 0.2 degrees of two-theta and P-XRD pattern as illustrated in figure-4.
  • the fifth aspect of the present invention provide a process for the preparation of pre- mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
  • step-a) the suitable acid is same as defined in step-a) of the fourth aspect of the present invention.
  • step-b) the suitable hydrochloric acid source is same as defined in step-b) of the fourth aspect of the present invention.
  • the suitable cellulose derivatives is selected from cellulose acetate, cellulose
  • cellulose xanthate carboxy methyl cellulose, micro crystalline cellulose, methyl cellulose, ethyl cellulose and hydroxy ethyl cellulose,
  • step-e) the suitable solvent is same as defined in step-d) of the fourth aspect of the present invention.
  • the preferred embodiment of the present invention provides a process for the preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-l H-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
  • hydrochloride compound of formula- lb hydrochloride compound of formula- lb.
  • the process according to the present invention involves vilazodone hydrochloride form-XVI comprising of pharmaceutical excipient.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the stable form-XVI of vilazodone hydrochloride together with one or more pharmaceutically acceptable carriers, excipients or diluents.
  • the sixth aspect of the present invention provides MCC pre-mixed form of 5-[4-[4- (5 -cyano- 1 H-indol-3 -yl)buty 1] - 1 -piperazinyl] -2-benzofurancarboxamide hydrochloride compound of formula- lb.
  • the seventh aspect of the present invention provides a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient, which comprising of the following steps:
  • the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like;
  • the suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry
  • the suitable cellulose derivatives is selected from cellulose acetate, cellulose
  • cellulose xanthate carboxy methyl cellulose, micro crystalline cellulose, methyl cellulose, ethyl cellulose and hydroxy ethyl cellulose;
  • the suitable solvent is selected from ester solvents, ketone solvents, chloro solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof; preferably the suitable solvent is selected from ester solvents such as ethyl acetate.
  • the preferred embodiment of the present invention provides a process for the preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
  • step-(c) adding micro crystalline cellulose to the filtrate obtained in step-(c), e) distilling off the formic acid completely from the reaction mixture,
  • the eighth aspect of the present invention provides a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- 1 b with an excipient, which comprising of the following steps;
  • step a) the suitable acid is same as defined in step-a) of the seventh aspect of the present invention.
  • step-c) the suitable cellulose derivatives is same as defined in step-d) of the seventh aspect of the present invention.
  • step-e) the suitable solvent is same as defined in step-f) of the seventh of the present
  • the preferred embodiment of the present invention provides a process for the preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]- l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
  • the formic acid salt as well as its crystalline form-M of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofurancarboxamide of the present invention is useful in the preparation of pure Vilazodone as well as form-XVI of Vilazodone hydrochloride.
  • the formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofurancarboxamide of the present invention can be converted in to its freebase by treating with a suitable base or by using any known methods.
  • PXRD analysis of compound produced by the present invention were carried out using BRUKER/AXS X-Ray diffractometer using Cu Ka radiation of wavelength 1.5406 A° and continuous scan speed of 0.03°/min.
  • DSC Differential scanning calorimetric
  • a liquid chromatographic system is to be equipped with variable wavelength UV-detector; Column: Symmetry CI 8, 150 x 4.6mm, 3.5 ⁇ (or) equivalent; Flow rate: 1.0 ml/min; Wavelength: 242 nm; Column Temperature: 40°C; Injection volume: 5 ⁇ ,; Run time: 35 min; Diluent: Water : Isopropyl alcohol (1 : 1) v/v; Needle wash: Water : Isopropyl alcohol (1 : 1) v/v; Elution: Gradient; Mobile phase-A: Buffer (100%); Mobile phase-B: Acetonitrile: Buffer (70:30) v/v; Buffer: 2.72 grams of potassium dihydrogen phosphate and 3.0 grams of 1 -Octane sulphonic acid in 1000 ml of water. Adjust pH to 2.0 with diluted orthophosphoric acid and filtered through 0.22 ⁇ Nylon membrane filter paper and sonicate to degas it.
  • a liquid chromatographic system is to be equipped with variable wavelength UV-detector; Column: Symmetry C 18, 150 x 4.6mm, 3.5 ⁇ (or) equivalent; Flow rate: 1.0 ml/min; Wavelength: 242 nm; Column Temperature: 40°C; Injection volume: 5 ⁇ ,; Run time: 35 min; Diluent: Water : Isopropyl alcohol (1 :1) v/v; Needle wash: Water : Isopropyl alcohol (1 :1) v/v; Elution: Gradient; Mobile phase-A: Buffer (100%); Mobile phase-B: Acetonitrile: Buffer (70:30) v/v; Buffer: 2.72 grams of potassium dihydrogen phosphate and 3.0 grams of 1 -Octane sulphonic acid in 1000 ml of water. Adjust pH to 2.0 with diluted orthophosphoric acid and filtered through 0.22 ⁇ Nylon membrane filter paper and sonicate to degas it.
  • the compound produced by the present invention can be further micronized or milled to get the desired particle size to achieve desired solubility profile based on different forms of pharmaceutical composition requirements.
  • Techniques that may be used for particle size reduction include, but not limited to ball, roller and hammer mills, and jet mills. Milling or micronization may be performed before drying, or after the completion of drying of the product.
  • Example-1 Preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide [Formula-la]
  • Impurity Not detected; Unknown Impurity: 0.05 %.
  • Example-2 Preparation of Form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
  • Formic acid 250 ml was added to formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide (100 gms) obtained in example-1 at 25- 30°C and stirred for 15 minutes at the same temperature.
  • Slowly aqueous hydrochloric acid (34.5 ml) was added to the reaction mixture at 25-30°C. Filtered the reaction mixture through hy-flow bed and washed with formic acid (50 ml). To the obtained filtrate, slowly water (1000 ml) was added at 25-30°C and stirred for 2 hours at the same temperature.
  • Example-4 Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
  • Example-5 Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
  • Example-6 Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
  • Example-7 Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
  • Example-8 Preparation of Form-IV of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyI]-l- piperazinyl] -2-benzofuran carboxamide hydrochloride
  • Formic acid 250 ml was added to formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide (100 gms) at 25-30°C and stirred for 15 minutes at the same temperature.
  • Aqueous hydrochloric acid (34.5 ml) was slowly added to the reaction mixture at 25-30°C. Filtered the reaction mixture through hyflow bed and washed with formic acid (50 ml). To the obtained filtrate ⁇ Water (1000 ml) was slowly added to the filtrate at 25-30°C and stirred for 2 hours at the same temperature. Filtered the precipitated solid and washed with water.
  • aqueous hydrochloric acid was added at 25-30°C and stirred the reaction mixture for 2 hours at the same temperature. Filtered the solid and washed with water. Ethanol (1000 ml) was added to the obtained wet compound at 25-30°C. Heated the reaction mixture to 60-65°C and stirred for 2 hours at the same temperature. Cooled the reaction mixture to 25-30°C and stirred for 2 hours at the same temperature. Filtered the solid, washed with ethanol and dried to get the title compound.
  • Example-9 Preparation of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yl)butyl)piperazin-l- yl)benzofuran-2-carboxylate hydrochloric acid.
  • Example-10 Preparation of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yI)butyl)piperaziii-l- yI)benzofuran-2-carboxy!ate hydrochloric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to formic acid salt as well as its crystalline form of antidepressant drug i.e., 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide compound of formula-1a, which is useful in the preparation of 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula-1b and process for its preparation.

Description

Process for the preparation of polymorphs of 5-[4-[4-(5-cyano- lH-indol-3-vnbutyll-l-piperazinyll-2-benzofuran carboxamide hydrochloride
Related Applications:
This application claims the benefit of priority of our Indian patent application numbers 6150/CHE/2013 filed on 30th Dec. 2013 and 732/CHE/2014 filed on 17th Feb. 2014 which are incorporated herein by reference.
Field of the Invention:
The present invention provides a formic acid salt as well as its crystalline form of antidepressant drug i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la, which is useful in the preparation of 5-[4-[4-(5- cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb and process for its preparation.
Figure imgf000002_0001
. Formula- la Formula- lb
Back ground of Invention:
US 5,532,241 (hereafter referred to as "241 ") first disclosed 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide and its hydrochloride salt compound of formula- lb which is commonly known as Vilazodone hydrochloride, an antidepressant agent, which acts as a serotonin reuptake inhibitor.
"241" first disclosed the process for the preparation of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide and its hydrochloride salt compound of formula-lb by reacting 5-(4-(4-(5-cyano-lH-indol-3-yl)butyl)piperazin-l-yl)benzofuran-2- carboxylic acid with 2-chloro-l-methylpyridinium methanesulfonate in the presence of N- methyl pyrrolidine and ammonia gas to provide vilazodone as free base. Further, vilazodone free base is dissolved in propanolic hydrochloric acid solution to precipitate hydrochloride salt of compound of formula- lb.
US7834020 (hereafter referred to as "020") describes several crystalline forms of vilazodone hydrochloride, such as Form-I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XIII, XIV, XV and XVI and process for their preparation.
"020" discloses the process for the preparation of vilazodone hydrochloride form- XVI (hereafter referred to as "form-XVI") using freeze-drying and spray drying methods. The process for the preparation of vilazodone hydrochloride form-XVI by the said patent is critical, laborious, time consuming and not suitable for the commercial scale.
Hence in view of above, there is a need to find an efficient and industrially advantageous process which is commercial viable and which overcomes the problems associated with the prior art.
Discovering new polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, e.g., better processing or handling characteristics, improved dissolution profile or improved shelf-life.
The present invention involves the novel crystalline forms of as acid addition salts of vilazodone.
The present invention also provides novel acid addition salts of vilazodone in solid state form. The novel salts of vilazodone of the present invention can be used to prepare vilazodone free base in pure form, which in turn useful in the preparation of highly pure vilazodone hydrochloride.
Brief description of the invention:
The first aspect of the present invention is to provide formic acid salt of 5-[4-[4-(5- cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la and its crystalline form herein after designated as Form-M.
The second aspect of the present invention is to provide a process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la.
The third aspect of the present invention is to provide a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
The fourth aspect of the present invention is to provide an alternate process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofurancarboxamide hydrochloride compound of formula- lb. The fifth aspect of the present invention is to provide a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
The sixth aspect of the present invention is to provide a micro crystalline cellulose (MCC) pre-mixed 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient.
The seventh aspect of the present invention is to provide a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient.
The eighth aspect of the present invention is to provide a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient.
Brief description of figures:
Figure 1: Illustrates the PXRD pattern of crystalline Form-M of formic acid salt of 5-[4-[4-
(5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide.
Figure 2: Illustrates the DSC thermogram of crystalline Form-M of formic acid salt of 5-[4- [4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide.
Figure 3: Illustrates the IR spectrum of crystalline Form-M of formic acid salt of 5-[4-[4-(5- cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide.
Figure 4: Illustrates the PXRD pattern of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-3.
Figure 5: Illustrates the DSC thermogram of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-3.
Figure 6: Illustrates the PXRD pattern of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-4.
Figure 7: Illustrates the PXRD pattern of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-5 or example -6.
Figure 8: Illustrates the PXRD pattern of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH- indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride obtained according to example-7.
Figure 9: Illustrates the PXRD pattern of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yl)butyl) piperazin-l-yl)benzofuran-2-carboxylate hydrochloride
Detailed description of invention:
As used herein the term "suitable solvent" is selected from "alcoholic solvents" such as methanol, ethanol, isopropanol, n-propanol, n-butanol, iso-butanol, ethylene glycol and the like; "ester solvents" such as ethyl acetate, methyl acetate, n-butyl acetate, isobutyl acetate, sec-butyl acetate, isopropyl acetate and the like, "ether solvents" such as tetrahydrofuran, diethylether, methyl tert-butylether, 1 ,4-dioxane and the like; "hydrocarbon solvents" such as toluene, xylene, cyclohexane, hexane, heptane, n-pentane and the like; "chloro solvents" such as methylene chloride, ethylene dichloride, carbon tetrachloride, chloroform and the like; "polar aprotic solvents" such as dimethyl formamide, dimethylacetamide, dimethylsulfoxide and the like; "nitrile solvents" such as acetonitrile, propionitrile, isobutyronitrile and the like; "ketone solvents" such as acetone, methyl isobutyl ketone, methyl ethyl ketone; polar solvent such as water and the like. The suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry
HC1, ethyl acetate-HCl, IPA-HC1, ethanol-HCl, methanol-HCl.
As used herein the term "suitable acid" is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like.
The term "MCC" used throughout the document is defined as micro crystalline cellulose.
The first aspect of the present invention provides a formic acid salt of 5-[4-[4-(5- cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide and its crystalline form herein after designated as Form-M. The said crystalline form-M is characterized by: a) Its powder X-ray diffractogram having peaks at 7.2, 7.7, 8.5, 10.4, 11.9, 12.2, 14.4, 14.7, 15.5, 16.6, 17.2, 18.0, 19.1, 20.0, 20.5, 21.0, 21.4, 21.9, 23.2, 24.0, 24.6, 26.4, 27.0 and 29.3 and 29.9 degrees of two-theta as illustrated in figure- 1 ;
b) its DSC thermogram showing endotherm at 204.69°C as illustrated in figure-2;
c) its IR spectrum as illustrated in figure-3.
The second aspect of the present invention provides a process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la, comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding a suitable solvent to the reaction mixture,
c) stirring the reaction mixture,
d) filtering the precipitated solid and drying to provide formic acid salt of 5-[4-[4-(5- cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl]-2-benzofuran carboxamide.
Wherein,
in step-b) the suitable solvent is selected from ester solvents, ketone solvents, chloro solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof;.
The preferred embodiment of the present invention provides a process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide, comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding isopropanol to the reaction mixture,
c) stirring the reaction mixture,
d) filtering the precipitated solid and drying to provide formic acid salt of 5-[4-[4-(5- cyano- 1 H-indol-3-yl)butyl] - 1 -piperazinyl]-2-benzofurancarboxamide compound of formula- la. The preferred embodiment of the present invention provides a process for the preparation of crystalline Form-M of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide, comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding isopropanol to the reaction mixture,
c) stirring the reaction mixture,
d) filtering the precipitated solid and drying to provide crystalline form-M of formic acid salt of 5 - [4- [4-(5 -cyano- 1 H-indol-3 -y l)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide compound of formula- la.
The starting material i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide utilized in the present invention can be prepared by any of the known prior art process. The third aspect of the present invention provides a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]- l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps: a) Dissolving the formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl] -2-benzofuran carboxamide in a suitable acid,
b) adding a suitable hydrochloric acid source to the reaction mixture,
c) filtering the reaction mixture,
d) adding a suitable solvent to the filtrate obtained in step-c),
e) stirring the reaction mixture,
f) filtering the precipitated solid,
g) adding a suitable hydrochloric acid source to the solid obtained in step-f),
h) stirring the reaction mixture,
i) filtering the solid and drying to provide form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl] -2-benzofuran carboxamide hydrochloride compound of formula- lb.
Wherein,
in step-a) the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like;
in step-b) & g) the suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry HC1, ethyl acetate-HCl, IPA-HC1, ethanol-HCl, methanol-HCl;
in step-d) the suitable solvent is same as defined in step-b) of the second aspect of the present invention.
The preferred embodiment of the present invention provides a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]- 2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l - piperazinyl] -2-benzofuran carboxamide in formic acid,
b) adding aqueous hydrochloric acid to the reaction mixture,
c) filtering the reaction mixture,
d) adding water to the filtrate obtained in step-c),
e) stirring the reaction mixture,
f) filtering the precipitated solid, g) adding aqueous hydrochloric acid to the solid obtained in step-f),
h) stirring the reaction mixture,
i) filtering the solid and drying to provide form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l -piperazinyl] -2-benzofuran carboxamide hydrochloride compound of formula- lb.
The preferred embodiment of the present invention provides a process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]- 2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the crystalline form-M of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding aqueous hydrochloric acid to the reaction mixture,
c) filtering the reaction mixture,
d) adding water to the filtrate obtained in step-c),
e) stirring the reaction mixture,
f) filtering the precipitated solid,
g) adding aqueous hydrochloric acid to the solid obtained in step-f),
h) stirring the reaction mixture,
i) filtering the solid and drying to provide form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l -piperazinyl] -2-benzofuran carboxamide hydrochloride compound of formula- lb.
The fourth aspect of the present invention provides an alternate process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the 5- [4- [4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl] -2-benzofuran carboxamide in a suitable acid,
b) adding a suitable hydrochloric acid source to the reaction mixture,
c) filtering the reaction mixture, d) adding a suitable solvent to the filtrate obtained in step-(c),
e) stirring the reaction mixture,
f) filtering the precipitated solid and drying to provide form-XVI of 5-[4-[4-(5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
Wherein,
in step-a) the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like;
in step-b) the suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry
HC1, ethyl acetate-HCl, IPA-HC1, ethanol-HCl, methanol-HCl;
in step-d) the suitable solvent is selected from ester solvents, ketone solvents, chloro
solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof; preferably the suitable solvent is selected from polar solvents such as water.
The preferred embodiment of the present invention provides an alternate process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding hydrochloric acid to the reaction mixture,
c) filtering the reaction mixture,
d) adding water to the filtrate obtained in step-(c),
e) stirring the reaction mixture,
f) filtering the precipitated solid and drying to provide form-XVI of 5-[4-[4-(5-cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride compound of formula- lb.
Further, 5 - [4- [4-(5 -cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride form-XVI obtained according to the above aspect of the present invention is characterized by its X-ray powder diffractogram having peaks at 7.8, 8.6, 10.5, 12.3, 14.8, 16.6, 19.4, 20.1, 21.1, 22.4, 23.6, 24.3, 24.5, 26.7, 27.2 and 31.6 ± 0.2 degrees of two-theta and P-XRD pattern as illustrated in figure-4. The fifth aspect of the present invention provide a process for the preparation of pre- mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in a suitable acid,
b) adding a suitable hydrochloric acid source to the reaction mixture,
c) filtering the reaction mixture,
d) adding a suitable cellulose derivative to the filtrate obtained in step-(c),
e) adding a suitable solvent to the reaction mixture,
f) stirring the reaction mixture,
g) filtering the precipitated solid and drying to provide MCC pre-mixed form of 5-[4-[4- (5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
Wherein,
in step-a) the suitable acid is same as defined in step-a) of the fourth aspect of the present invention;
in step-b) the suitable hydrochloric acid source is same as defined in step-b) of the fourth aspect of the present invention;
in step-d) the suitable cellulose derivatives is selected from cellulose acetate, cellulose
nitrate, cellulose xanthate, carboxy methyl cellulose, micro crystalline cellulose, methyl cellulose, ethyl cellulose and hydroxy ethyl cellulose,
in step-e) the suitable solvent is same as defined in step-d) of the fourth aspect of the present invention.
The preferred embodiment of the present invention provides a process for the preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-l H-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding hydrochloric acid to the reaction mixture,
c) filtering the reaction mixture,
d) adding micro crystalline cellulose to the filtrate obtained in step-(c),
e) adding water to the reaction mixture,
f) stirring the reaction mixture,
g) filtering the precipitated solid and drying to provide MCC pre-mixed form of 5-[4-[4- (5-cyano-lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofurancarboxamide
hydrochloride compound of formula- lb.
The process according to the present invention involves vilazodone hydrochloride form-XVI comprising of pharmaceutical excipient.
Further, the present invention also provides a pharmaceutical composition comprising the stable form-XVI of vilazodone hydrochloride together with one or more pharmaceutically acceptable carriers, excipients or diluents.
The sixth aspect of the present invention provides MCC pre-mixed form of 5-[4-[4- (5 -cyano- 1 H-indol-3 -yl)buty 1] - 1 -piperazinyl] -2-benzofurancarboxamide hydrochloride compound of formula- lb.
The P-XRD of pre-mixed form of vilazodone hydrochloride obtained according to the present invention is shown in figure-7.
The seventh aspect of the present invention provides a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb with an excipient, which comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in a suitable acid, b) adding a suitable hydrochloric acid source to the reaction mixture,
c) filtering the reaction mixture,
d) adding a suitable cellulose derivative to the filtrate obtained in step-(c),
e) distilling off the acid completely from the reaction mixture,
f) adding a suitable solvent to the compound obtained in step-(e),
g) stirring the reaction mixture,
h) filtering the precipitated solid and drying to provide MCC pre-mixed form of 5-[4-[4- (5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
Wherein,
in step-a) the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like;
in step-b) the suitable hydrochloric acid source is selected from HC1 gas, aqueous HC1, dry
HC1, ethyl acetate-HCl, IPA-HC1, ethanol-HCl, methanol-HCl;
in step-d) the suitable cellulose derivatives is selected from cellulose acetate, cellulose
nitrate, cellulose xanthate, carboxy methyl cellulose, micro crystalline cellulose, methyl cellulose, ethyl cellulose and hydroxy ethyl cellulose;
in step-f) the suitable solvent is selected from ester solvents, ketone solvents, chloro solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof; preferably the suitable solvent is selected from ester solvents such as ethyl acetate.
The preferred embodiment of the present invention provides a process for the preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding hydrochloric acid to the reaction mixture,
c) filtering the reaction mixture,
d) adding micro crystalline cellulose to the filtrate obtained in step-(c), e) distilling off the formic acid completely from the reaction mixture,
f) adding ethyl acetate to the compound obtained in step-(e),
g) stirring the reaction mixture,
h) filtering the precipitated solid and drying to provide MCC pre-mixed form of 5-[4-[4- (5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
The eighth aspect of the present invention provides a process for the preparation of pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- 1 b with an excipient, which comprising of the following steps;
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride in a suitable acid,
b) filtering the reaction mixture,
c) adding a suitable cellulose derivative to the filtrate obtained in step-(b),
d) distilling off the acid completely from the reaction mixture,
e) adding a suitable solvent to the compound obtained in step-(d),
f) stirring the reaction mixture,
g) filtering the precipitated solid and drying to provide MCC pre-mixed form of 5-[4-[4- (5-cyano-lH-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
Wherein,
in step a) the suitable acid is same as defined in step-a) of the seventh aspect of the present invention;
in step-c) the suitable cellulose derivatives is same as defined in step-d) of the seventh aspect of the present invention;
in step-e) the suitable solvent is same as defined in step-f) of the seventh of the present
invention. The preferred embodiment of the present invention provides a process for the preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]- l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, which comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride in formic acid,
b) filtering the reaction mixture,
c) adding micro crystalline cellulose to the filtrate obtained in step-(b),
d) distilling off the formic acid completely from the reaction mixture,
e) adding ethyl acetate to the compound obtained in step-(d),
f) stirring the reaction mixture,
g) filtering the precipitated solid and drying to provide MCC pre-mixed form of 5-[4-[4- (5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
The formic acid salt as well as its crystalline form-M of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofurancarboxamide of the present invention is useful in the preparation of pure Vilazodone as well as form-XVI of Vilazodone hydrochloride.
The formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofurancarboxamide of the present invention can be converted in to its freebase by treating with a suitable base or by using any known methods.
The crystalline form-XVI 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide hydrochloride compound of formula- lb obtained from the process of the present invention is stable at room temperature.
PXRD analysis of compound produced by the present invention were carried out using BRUKER/AXS X-Ray diffractometer using Cu Ka radiation of wavelength 1.5406 A° and continuous scan speed of 0.03°/min.
Differential scanning calorimetric (DSC) analysis was performed with Q10 V9.6 Build 290 calorimeter. Samples of about 2 to 3 milligrams held in a closed pan were analyzed at a heating rate of 10° per minute. HPLC Method of Analysis of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yI)butyl]- l-piperazinyI]-2-benzofuran carboxamide.
Apparatus: A liquid chromatographic system is to be equipped with variable wavelength UV-detector; Column: Symmetry CI 8, 150 x 4.6mm, 3.5 μηα (or) equivalent; Flow rate: 1.0 ml/min; Wavelength: 242 nm; Column Temperature: 40°C; Injection volume: 5 μΐ,; Run time: 35 min; Diluent: Water : Isopropyl alcohol (1 : 1) v/v; Needle wash: Water : Isopropyl alcohol (1 : 1) v/v; Elution: Gradient; Mobile phase-A: Buffer (100%); Mobile phase-B: Acetonitrile: Buffer (70:30) v/v; Buffer: 2.72 grams of potassium dihydrogen phosphate and 3.0 grams of 1 -Octane sulphonic acid in 1000 ml of water. Adjust pH to 2.0 with diluted orthophosphoric acid and filtered through 0.22μπι Nylon membrane filter paper and sonicate to degas it.
5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula-lb.
Apparatus: A liquid chromatographic system is to be equipped with variable wavelength UV-detector; Column: Symmetry C 18, 150 x 4.6mm, 3.5 μιη (or) equivalent; Flow rate: 1.0 ml/min; Wavelength: 242 nm; Column Temperature: 40°C; Injection volume: 5 μΐ,; Run time: 35 min; Diluent: Water : Isopropyl alcohol (1 :1) v/v; Needle wash: Water : Isopropyl alcohol (1 :1) v/v; Elution: Gradient; Mobile phase-A: Buffer (100%); Mobile phase-B: Acetonitrile: Buffer (70:30) v/v; Buffer: 2.72 grams of potassium dihydrogen phosphate and 3.0 grams of 1 -Octane sulphonic acid in 1000 ml of water. Adjust pH to 2.0 with diluted orthophosphoric acid and filtered through 0.22μηι Nylon membrane filter paper and sonicate to degas it.
The compound produced by the present invention can be further micronized or milled to get the desired particle size to achieve desired solubility profile based on different forms of pharmaceutical composition requirements. Techniques that may be used for particle size reduction include, but not limited to ball, roller and hammer mills, and jet mills. Milling or micronization may be performed before drying, or after the completion of drying of the product.
The process described in the present invention was demonstrated in examples illustrated below. These examples are provided as illustration only and therefore should not be construed as limitation of the scope of the invention.
Examples: Example-1: Preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide [Formula-la]
Formic acid (300 ml) was added to 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide (100 gms) at 25-30°C and stirred for 15 minutes. Isopropanol (1500 ml) was added to the reaction mixture at 25-30°C and stirred for 2-3 hours at the same temperature. Filtered the precipitated solid, washed with isopropanol and dried to get the title compound. Yield: 95.5 gms. Melting point: 199-204°C.
Purity by HPLC 99.65 %; Diamide Impurity: Not detected; Acid Impurity: 0.04 %; Ester
Impurity: Not detected; Unknown Impurity: 0.05 %.
The PXRD of the obtained compound is shown in figure- 1. Example-2: Preparation of Form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
Formic acid (250 ml) was added to formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide (100 gms) obtained in example-1 at 25- 30°C and stirred for 15 minutes at the same temperature. Slowly aqueous hydrochloric acid (34.5 ml) was added to the reaction mixture at 25-30°C. Filtered the reaction mixture through hy-flow bed and washed with formic acid (50 ml). To the obtained filtrate, slowly water (1000 ml) was added at 25-30°C and stirred for 2 hours at the same temperature. Filtered the precipitated solid and washed with water. To the obtained wet solid, aqueous hydrochloric acid was added at 25-30°C and stirred the reaction mixture for 1 ½ hours at the same temperature. Filtered the solid, washed with water and dried to get the title compound. Yield: 96.2 gms. Melting point 284-288°C.
Formic acid content: 1100 ppm.
Particle size distribution: Di0: 16.69 μηι; D50: 78.92 μηι; D90: 144.99 μπν, Example-3: Preparation of Form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide (10 gms) was added to formic acid (25 ml) at 25-30°C and stirred for 15 minutes at the same temperature. Hydrochloric acid (2.3 ml) was slowly added to the reaction mixture at 25- 30°C. Filtered the reaction mixture and washed with formic acid (5.0 ml) at 25-30°C. Water (100 ml) was slowly added to the obtained filtrate at 25-30°C and stirred for 1 hour at the same temperature. Filtered the precipitated solid and washed with water. To the obtained wet solid, water (100 ml) was added at 25-30°C and stirred for 1 hour at the same temperature. Filtered the solid, washed with water and dried to get the title compound. Yield: 8.1 gms. The PXRD of the obtained compound is shown in figure-4.
Water content: 7.2 % w/w.
Formic acid content: 4417 ppm.
Purity by HPLC: 99.97 %.
Particle size distribution: D]0: 6.74 μηι; D50: 31.20 μπι; D%: 60.99 μπι;
Example-4: Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide (10 gms) was added to formic acid (25 ml) at 25-30°C and stirred for 15 minutes at the same temperature. Hydrochloric acid (2.3 ml) was slowly added to the reaction mixture at 25- 30°C. Filter the reaction mixture and washed with formic acid (5.0 ml) at 25-30°C. Micro crystalline cellulose (10 gms), followed by water (100 ml) was slowly added to the obtained filtrate at 25-30°C and stirred for 1 hour at the same temperature. Filtered the precipitated solid and washed with water. To the obtained wet solid, water (100 ml) was added at 25-30°C and stirred for 1 hour at the same temperature. Filtered the solid, washed with water and dried to get the title compound. Yield: 8.0 gms.
The PXRD of the obtained compound is shown in figure-6.
Water content: 7.6 % w/w.
Formic acid content: 3465 ppm.
Purity by HPLC: 99.95 %. Example-5: Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
5-[4-[4-(5-cyano- 1 H-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofuran carboxamide ( 10 gms) was added to formic acid (30 ml) at 25-30°C and stirred for 15 minutes at the same temperature. Hydrochloric acid (2.5 ml) was slowly added to the reaction mixture at 25- 30°C. Filtered the reaction mixture and washed with formic acid (10 ml) at 25-30°C Micro crystalline cellulose (20.0 gms) was added to the filtrate at 25-30°C. Distilled off the formic acid completely from the reaction mixture under reduced pressure below 85°C. Ethyl acetate (300 ml) was added to the obtained compound at 15-20°C and stirred for 30 minutes at the same temperature. Filtered the solid, washed with ethyl acetate and dried to get the title compound. Yield: 28.9.0 gms.
The PXRD of the obtained compound is shown in figure-7.
Example-6: Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride (10 gms) was added to formic acid (30 ml) at 25-30°C and stirred for 15 minutes at the same temperature. Filtered the reaction mixture and washed with formic acid (10 ml) at 25-30°C. Micro crystalline cellulose (20.0 gms) was added to the filtrate at 25- 30°C. Distilled off the formic acid completely from the reaction mixture under reduced pressure below 85°C. Ethyl acetate (300 ml) was added to the obtained compound at 15-20°C and stirred for 30 minutes at the same temperature. Filtered the solid, washed with ethyl acetate and dried to get the title compound. Yield: 29.2. gms.
The PXRD of the obtained compound is shown in figure-7.
Example-7: Preparation of MCC pre-mixed form of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride [Formula-lb]
5 - [4- [4-(5 -cyano- 1 H-indol-3 -y l)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride (10 gms) was added to formic acid (30 ml) at 25-30°C and stirred for 15 minutes at the same temperature. Filter the reaction mixture and washed with formic acid (10 ml) at 25-30°C. Micro crystalline cellulose (20.0 gms) was added to the reaction mixture at 25-30°C. Distilled off the formic acid completely from the reaction mixture under reduced pressure below 85°C. Water (300 ml) was added to the obtained compound at 15-20°C and stirred for 30 minutes at the same temperature. Filtered the solid, washed with water and dried to get the title compound. Yield: 29.2. gms.
The PXRD of the obtained compound is shown in figure-8.
Example-8: Preparation of Form-IV of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyI]-l- piperazinyl] -2-benzofuran carboxamide hydrochloride
Formic acid (250 ml) was added to formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide (100 gms) at 25-30°C and stirred for 15 minutes at the same temperature. Aqueous hydrochloric acid (34.5 ml) was slowly added to the reaction mixture at 25-30°C. Filtered the reaction mixture through hyflow bed and washed with formic acid (50 ml). To the obtained filtrate^ Water (1000 ml) was slowly added to the filtrate at 25-30°C and stirred for 2 hours at the same temperature. Filtered the precipitated solid and washed with water. To the obtained wet solid, aqueous hydrochloric acid was added at 25-30°C and stirred the reaction mixture for 2 hours at the same temperature. Filtered the solid and washed with water. Ethanol (1000 ml) was added to the obtained wet compound at 25-30°C. Heated the reaction mixture to 60-65°C and stirred for 2 hours at the same temperature. Cooled the reaction mixture to 25-30°C and stirred for 2 hours at the same temperature. Filtered the solid, washed with ethanol and dried to get the title compound.
Yield: 95 gms; Melting point: 280-284°C.
Example-9: Preparation of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yl)butyl)piperazin-l- yl)benzofuran-2-carboxylate hydrochloric acid.
A mixture of ethyl 5-(piperazin-l -yl)benzofuran-2-carboxylate hydrochloride (23 kgs), acetonitrile (160 lit), potassium carbonate (10.1 kgs), triethylamine (7.4 kgs), 3-(4- chlorobutyl)- lH-indole-5-carbonitrile (17.3 kgs), potassium iodide (1.2 kgs) and tetrabutyl ammonium bromide (1.2 kgs were stirred for 30 hours at 75-80°C. Distilled off solvent completely from the reaction mixture under reduced pressure. Water and then ethyl acetate was added to the reaction mixture at 25-30°C and stirred for 15 minutes at the same temperature. Both the organic and aqueous layers were separated and washed the organic layer with aqueous sodium chloride solution. Distilled off the solvent completely from the organic layer under reduced pressure and co-distilled with acetone. Acetone (1 15 lit) was added to the obtained compound at 25-30°C and stirred for 15 minutes at the same temperature. Adjusted the pH of the reaction mixture to 2.5 by using aqueous hydrochloric acid solution at 25-30°C and stirred for 3 hours at the same temperature. Filter the precipitated solid, wash with acetone. To the obtained solid, water (9.5 lit was added at 25- 30°C. Heated the reaction mixture to 60-65°C and stirred for 20 minutes at the same temperature. Cooled the reaction mixture to 25-30°C and stirred for 45 minutes at the same temperature. Filter the solid, wash with water. Ethylacetate (104 lit) and formic acid(l 1.5 lit) was added to the obtained solid at 25-30°C. Heated the reaction mixture to reflux temperature and stirred for 20 minutes at the same temperature. Cooled the reaction mixture to 25-30°C and stirred for 60 minutes at the same temperature. Filter the solid, wash with ethyl acetate and then dried to get the title compound. Yield: 20 kgs.
The PXRD of the obtained compound is shown in figure-9.
Example-10: Preparation of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yI)butyl)piperaziii-l- yI)benzofuran-2-carboxy!ate hydrochloric acid
A mixture of ethyl 5-(piperazin-l-yl)benzofuran-2-carboxylate hydrochloride (23 kgs), acetonitrile (160 lit), potassium carbonate (10.1 kgs), triethylamine (7.4 kgs), 3-(4- chlorobutyl)- lH-indole-5-carbonitrile (17.3 kgs), potassium iodide (1.2 kgs) and tetrabutyl ammonium bromide (1.2 kgs were stirred for 30 hours at 75-80°C. Distilled off solvent completely from the reaction mixture under reduced pressure. Water and then ethyl acetate was added to the reaction mixture at 25-30°C and stirred for 15 minutes at the same temperature. Both the organic and aqueous layers were separated and washed the organic layer with aqueous sodium chloride solution. Distilled off the solvent completely from the organic layer under reduced pressure and co-distilled with acetone. Acetone (1 15 lit) was added to the obtained compound at 25-30°C and stirred for 15 minutes at the same temperature. Adjusted the pH of the reaction mixture to 2.5 by using aqueous hydrochloric acid solution at 25-30°C and stirred for 3 hours at the same temperature. Filter the precipitated solid, wash with acetone. To the obtained solid, water (9.5 lit was added at 25- 30°C. Heated the reaction mixture to 60-65 °C and stirred for 20 minutes at the same temperature. Cooled the reaction mixture to 25-30°C and stirred for 45 minutes at the same temperature. Filter the solid, wash with water. Ethyl acetate (104 lit) was added to the obtained solid at 25-30°C. Heated the reaction mixture to reflux temperature and stirred for 20 minutes at the same temperature. Cooled the reaction mixture to 25-30°C and stirred for 60 minutes at the same temperature. Filter the solid, wash with ethyl acetate and then dried to get the title compound. Yield: 21 kgs
The PXRD of the obtained compound is shown in figure-9. Example-11: Preparation of 5-[4-[4-(5-cyano-IH-indol-3-yl)butyI]-l-piperazinyl]-2- benzofuran carboxamide
Mixture of dimethylformamide (450 ml) and ethyl 5-(4-(4-(5-cyano-lH-indol-3- yl)butyl)piperazin-l-yl)benzofuran-2-carboxylate hydrochloride (30.0 g) was cooled to 0-5°C and stirred for 20 minutes. Formamide (48.7 g) and followed by sodium methoxide in methanol ( 1.6 g) was added to reaction mixture at 0-5 °C and stirred the reaction mixture for 1 hour at same temperature. After completion of the reaction, water (900 ml) was added to the reaction mixture and stirred for 45 minutes at 25-30°C. Filtered the precipitated solid, washed with water and dried to get the title compound as crystalline solid. Yield: 25.7 gm; Melting point: 203- 209°C.

Claims

We Claim:
1. A process for the preparation of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la, comprising of the following steps:
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding a suitable solvent to the reaction mixture,
c) stirring the reaction mixture,
d) filtering the precipitated solid and drying to provide formic acid salt of 5-[4-[4-(5- cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la.
2. A process according to claim- 1, wherein,
in step-b) the suitable solvent is selected from ester solvents, ketone solvents, chloro
solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof; preferably the suitable solvent is selected from polar solvents such as water.
3. A process for the preparation of crystalline form-M of formic acid salt of 5-[4-[4-(5- cyano- lH-indol-3-yl)butyl]- 1 -piperazinyl]-2-benzofurancarboxamide compound of formula- la, comprising of the following steps;
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
a) adding isopropanol to the reaction mixture,
b) stirring the reaction mixture,
c) filtering the precipitated solid and drying to provide crystalline form-M of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide compound of formula- la.
4. A process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding aqueous hydrochloric acid to the reaction mixture,
c) adding water to the reaction mixture,
d) stirring the reaction mixture,
e) filtering the precipitated solid,
f) adding aqueous hydrochloric acid to the solid obtained in step-e),
g) stirring the reaction mixture,
h) filtering the solid and drying to provide form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
A process for the preparation of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the crystalline form-M of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding aqueous hydrochloric acid to the reaction mixture,
c) adding water to the reaction mixture,
d) stirring the reaction mixture,
e) filtering the precipitated solid,
f) adding aqueous hydrochloric acid to the solid obtained in step-e),
g) stirring the reaction mixture,
h) filtering the solid and drying to provide form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
A process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps: a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in a suitable acid,
b) adding suitable hydrochloric acid source to the reaction mixture,
c) adding suitable solvent to the reaction mixture,
d) stirring the reaction mixture,
e) filtering the precipitated solid and drying to provide form-XVI of 5-[4-[4-(5-cyano- lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
7. A process according to claim-6,
in step-a) the suitable acid is selected from formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid and the like,
in step-b) the suitable hydrochloric acid source is selected from HCl gas, aqueous HCl, dry HCl, ethyl acetate-HCl, IPA-HC1, ethanol-HCl, methanol-HCl;
in step-c) the suitable solvent is selected from ester solvents, ketone solvents, chloro
solvents, alcohol solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents like water and mixture thereof; preferably the suitable solvent is selected from polar solvents such as water.
8. A process for the preparation of form-XVI of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l -piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding hydrochloric acid to the reaction mixture,
c) adding water to the reaction mixture,
d) stirring the reaction mixture,
e) filtering the precipitated solid and drying to provide form-XVI of 5-[4-[4-(5-cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride compound of formula-lb.
9. A process for the preparation of crystalline form-IV of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb, comprising of the following steps;
a) Dissolving the crystalline form-M of formic acid salt of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide in formic acid,
b) adding aqueous hydrochloric acid to the reaction mixture,
c) adding water to the reaction mixture,
d) stirring the reaction mixture,
e) filtering the precipitated solid,
f) adding aqueous hydrochloric acid to the solid obtained in step-e),
g) adding ethanol to the solid obtained in step-f),
h) heating the reaction mixture,
i) cooling the reaction mixture,
j) filtering the solid and drying to provide form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula- lb.
10. The formic acid salt of 5-[4-[4-(5-cyano-lHindol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide:
Figure imgf000026_0001
1 1. Crystalline formic acid salt of 5-[4-[4-(5-cyano-lHindol-3-yl)butyl]-l-piperazinyl]-2- benzofuran carboxamide.
12. The crystalline form (Form-M) according to claim- 11 , is characterized by:
i. its X-ray powder diffractogram having peaks at 7.7, 8.5, 10.4, 11.9, 14.4, 15.5, 18.0, 19.1 , 20.0, 21.0, 21.9, 24.0, 26.4, 27.0 and 29.3 degrees of two-theta as illustrated in figure- 1 ; ii. its DSC thermogram showing endotherm as illustrated in figure-2;
iii. its IR spectrum as illustrated in figure-3.
13. Crystalline form-M of formic acid salt of 5-[4-[4-(5-cyano-lHindol-3-yl)butyl]-l- piperazinyl]-2-benzofuran carboxamide of claim- 11 is further characterized by its X- ray powder diffractogram having peaks at 7.2, 8.5, 10.4, 11.9, 12.2, 14.4, 14.7, 15.5, 16.6, 17.2, 18.0, 19.1, 20.0, 20.5, 21.0, 21.4, 21.9, 23.2, 24.0, 24.6, 26.4, 27.0, 29.3 and 29.9 degrees of two-theta as illustrated in figure- 1.
14. 5 - [4- [4-(5 -cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride form-XVI obtained according to any of the preceding claims is characterized by its X-ray powder diffractogram having peaks at 7.8, 8.6, 10.5, 12.3, 14.8, 16.6, 19.4, 20.1 , 21.1, 22.4, 23.6, 24.3, 24.5, 26.7, 27.2 and 31.6 ± 0.2 degrees of two-theta and P-XRD pattern as illustrated in figure-4.
15. 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride form-XVI obtained according to any of the preceding claims is further characterized by its DSC thermogram showing endotherms as illustrated in figure-5.
16. 5-[4-[4-(5-cyano- lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride form-XVI obtained according to any of the preceding claims having water content about 6.0 weight % to 8.0 weight %.
17. 5 - [4- [4-(5 -cyano- 1 H-indol-3 -yl)butyl] - 1 -piperazinyl] -2-benzofuran carboxamide hydrochloride Form-XVI obtained according to any of the preceding claims having purity by HPLC greater than 99.95 %.
18. A MCC pre-mixed vilazodone hydrochloride.
19. A MCC pre-mixed vilazodone hydrochloride having P-XRD pattern as illustrated in figure-7.
20. Use of MCC pre-mixed vilazodone hydrochloride in the preparation of pharmaceutical composition.
21. Use of formic acid salt as well as its crystalline form-M of 5-[4-[4-(5-cyano-lH-indol- 3-yl)butyl]-l-piperazinyl]-2-benzofurancarboxamide obtained according to any of the preceding claims in the preparation of pure Vilazodone free base as well as Vilazodone hydrochloride form-XVI.
22. Particle size distribution of crystalline form-XVI of 5-[4-[4-(5-cyano-lH-indol-3- yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride having D(0.9) less than 200 μηι, preferably less than 150 μηι.
Dated this day ^° of December 2014
Figure imgf000028_0001
(Srinivasan Thirumalai Raj an) MSN Laboratories Private Limited.
PCT/IN2014/000801 2013-12-30 2014-12-29 Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride WO2015102019A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN6150/CHE/2013 2013-12-30
IN732/CHE/2014 2014-02-17
IN732CH2014 IN2014CH00732A (en) 2014-02-17 2014-12-29
IN6150CH2013 IN2013CH06150A (en) 2013-12-30 2014-12-29

Publications (2)

Publication Number Publication Date
WO2015102019A2 true WO2015102019A2 (en) 2015-07-09
WO2015102019A3 WO2015102019A3 (en) 2015-08-27

Family

ID=53494170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000801 WO2015102019A2 (en) 2013-12-30 2014-12-29 Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride

Country Status (1)

Country Link
WO (1) WO2015102019A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76758C2 (en) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Polymorph forms of hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine
AU2006249921A1 (en) * 2005-05-26 2006-11-30 Vertex Pharmaceuticals Incorporated Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
CN102977083A (en) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 New crystal form XVII of 1-(4-(5-cyanoindole-3-yl) butyl)-4-(2-carbamyl-benzofuran-5-yl)-piperazine hydrochloride and preparation method of new crystal form XVII

Also Published As

Publication number Publication date
WO2015102019A3 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
US9283210B2 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
US8779161B2 (en) Asenapine maleate
US20200347047A1 (en) Solid state form of valbenazine
WO2016016766A2 (en) A process for the preparation of isavuconazonium or its salt thereof
EP3567038B1 (en) Process for the preparation of quinazolinyl derivatives
US9624207B2 (en) Polymorphs of azilsartan medoxomil
WO2013132511A1 (en) Novel polymorph of lurasidone hydrochloride
US10550107B2 (en) Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof
EP2900658A2 (en) Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts
US9580414B2 (en) Salts and hydrates of antipsychotics
US20180273499A1 (en) Salts and solid state forms of vortioxetine
JP2005507858A (en) How to produce zaleplon
WO2015128882A2 (en) Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
US10301353B2 (en) Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2013150544A2 (en) Ivabradine hydrochloride solid dispersion
WO2012090221A1 (en) Novel salts of imatinib
WO2015102019A2 (en) Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride
WO2021117062A1 (en) Process for the preparation of 4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7- diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and its polymorphs
US10752618B2 (en) Process for the preparation of pure and stable crystalline Raltegravir potassium form 3
EP3002286B1 (en) Preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof
WO2012142983A1 (en) Optically active salts of (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahydro-3ah- cyclopenta-[d] [1,3]dioxol-4-ol and a method of their preparation
EP2277866A1 (en) Process for preparing telmisartan
US20240199615A1 (en) Novel crystalline polymorphs of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
WO2022215083A1 (en) Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof
WO2022208552A1 (en) Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14877207

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14877207

Country of ref document: EP

Kind code of ref document: A2